Understanding rs2070959: Genetic Insights into Gallstone Risk
The genetic variant rs2070959 is a single nucleotide polymorphism located within the UGT1A6 gene. Research has associated this variant with altered enzyme activity and potential variations in bilirubin levels, which may influence an individual's susceptibility to gallstone-related conditions.
What each genotype means
Typical bilirubin processing
This genotype is associated with standard processing of bilirubin in the body. Research into this variant often focuses on how genetic factors influence bilirubin levels and potential gallstone risk, though individual outcomes are influenced by many factors including diet and lifestyle.
This is a common genotype found in many global populations, though exact frequencies vary by ancestry.
Intermediate bilirubin profile
Carriers of this genotype may show intermediate associations with bilirubin metabolism compared to other groups. Because this variant is linked to gallstone risk, maintaining a balanced diet and discussing any concerns about digestive health with a clinician is a proactive approach.
This heterozygous genotype is frequently observed across diverse populations.
Varied bilirubin metabolism
This genotype is associated with variations in bilirubin levels that may influence the risk of developing gallstones. While this genetic predisposition is noted in research, it is not a diagnosis; you should discuss your overall metabolic health and any symptoms with your healthcare provider.
This genotype is present in a significant portion of the population, with frequencies varying notably between different ethnic groups.
What is rs2070959?
The variant rs2070959 is a specific change in the DNA sequence located within the UGT1A6 gene. In genetics, a single nucleotide polymorphism (SNP) represents a variation at a single position in the DNA chain. This particular variant is often referred to in scientific literature as p.Thr181Ala, describing the resulting change in the amino acid sequence of the UGT1A6 protein. The UGT1A6 gene provides instructions for making an enzyme that plays a critical role in the glucuronidation process, a metabolic pathway that helps the body process and eliminate various substances, including bilirubin, a yellow pigment formed during the normal breakdown of red blood cells. By altering the structure of this enzyme, the rs2070959 variant can influence how efficiently the body conjugates and clears these compounds, which is a fundamental aspect of liver metabolism.
The Role of UGT1A6
The UGT1A6 enzyme is part of a family of enzymes known as UDP-glucuronosyltransferases. These enzymes are primarily located in the liver and are essential for detoxification and the excretion of endogenous and exogenous compounds. By attaching a glucuronic acid molecule to these substances, the enzyme makes them more water-soluble, allowing them to be easily excreted through bile or urine. When the function of UGT1A6 is reduced, the body's ability to process bilirubin and other substrates is impaired. This impairment can lead to changes in serum bilirubin levels. Because bilirubin metabolism is closely tied to the composition of bile, any disruption in this pathway can theoretically affect the stability of bile, potentially influencing the formation of gallstones. Understanding this gene's function is key to grasping why specific genetic variations are studied in the context of liver and gallbladder health.
Research and Associations
Scientific research has identified rs2070959 as a variant of interest in studies concerning gallstone disease. Specifically, some studies have observed that individuals carrying this variant may have a higher risk of gallstone-related cholecystectomy, which is the surgical removal of the gallbladder. Research indicates that the rs2070959 variant is associated with a reduction in UGT1A6 enzyme activity, sometimes estimated at 30% to 50% in certain populations. While these statistical associations are notable, it is important to recognize that gallstone disease is a complex, multifactorial condition influenced by a combination of genetics, diet, lifestyle, and environmental factors. The evidence linking this specific SNP to clinical outcomes is considered moderate, and researchers continue to investigate how these genetic predispositions interact with other biological markers to influence overall health outcomes.
Interpreting Your Genetic Information
If you have information about your rs2070959 genotype, it is important to view it within the context of your overall health. Genetic variants are not diagnostic tools; they represent statistical probabilities rather than certainties. Having a specific genotype does not mean you will develop gallstones, nor does the absence of it guarantee you will not. Many people with various genotypes live healthy lives without ever experiencing gallbladder issues. This information is best used as a starting point for a conversation with a healthcare professional. If you have concerns about your digestive health, bilirubin levels, or family history of gallbladder disease, consult your doctor. They can provide personalized guidance based on your clinical history, physical exams, and appropriate diagnostic testing, rather than relying on genetic data alone.
How common is this variant?
The frequency of the rs2070959 variant is variable across different global populations, with specific allele distributions often differing significantly between ancestral groups.
Frequently asked questions
Does having the rs2070959 variant mean I will get gallstones?
No, having this variant does not mean you will develop gallstones. Gallstone disease is complex and influenced by many factors, including diet, weight, age, and overall health, not just a single genetic variant.
Can I change my UGT1A6 enzyme activity through diet?
While some research explores how diet interacts with genetic variants, there is no established dietary protocol to specifically 'fix' or change the activity of the UGT1A6 enzyme. Always consult a registered dietitian or doctor before making significant changes to your diet.
Should I get tested for this SNP?
Routine testing for this SNP is not currently recommended for the general population. Genetic testing should be discussed with a healthcare provider if there is a specific clinical reason or family history that warrants investigation.
What should I do if I am worried about my gallbladder health?
If you are concerned about your gallbladder health, you should schedule an appointment with your primary care physician or a gastroenterologist. They can perform appropriate clinical evaluations, such as blood tests or imaging, which are far more informative than genetic data alone.
Sources & further reading
Educational information only, last refreshed 10/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2070959?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in APOE
Non-coding regulatory variant in APOE strongly associated with cognitive healthspan, survival past 90, and lipid homeostasis.
Together with rs7412, the C allele at rs429358 establishes the APOE epsilon 4 haplotype, conferring dose-dependent susceptibility to late-onset Alzheimer disease and cardiovascular disease.
This variant (c.548G>C, p.Gly183Ala) in the APOE gene is classified as likely pathogenic and is associated with familial type 3 hyperlipoproteinemia (dysbetalipoproteinemia).
This variant in the APOE locus has been identified as a significant marker associated with Alzheimer's disease neuropathology using genomic informational field theory.
Variant in the APOE/TOMM40 locus associated with late-onset Alzheimer's disease risk.
Downstream variant in the APOE region associated with lipid metabolism profiles and healthspan indicators.